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Abstract: As part of the Heart Healthy Lenoir Project, we developed a practice level intervention
to improve blood pressure control. The goal of this study was: (i) to determine if single nucleotide
polymorphisms (SNPs) that associate with blood pressure variation, identified in large studies, are
applicable to blood pressure control in subjects from a rural population; (ii) to measure the association
of these SNPs with subjects’ responsiveness to the hypertension intervention; and (iii) to identify
other SNPs that may help understand patient-specific responses to an intervention. We used
a combination of candidate SNPs and genome-wide analyses to test associations with either baseline
systolic blood pressure (SBP) or change in systolic blood pressure one year after the intervention in
two genetically defined ancestral groups: African Americans (AA) and Caucasian Americans (CAU).
Of the 48 candidate SNPs, 13 SNPs associated with baseline SBP in our study; however, one candidate
SNP, rs592582, also associated with a change in SBP after one year. Using our study data, we identified
4 and 15 additional loci that associated with a change in SBP in the AA and CAU groups, respectively.
Our analysis of gene-age interactions identified genotypes associated with SBP improvement within
different age groups of our populations. Moreover, our integrative analysis identified AQP4-AS1
and PADI2 as genes whose expression levels may contribute to the pleiotropy of complex traits
involved in cardiovascular health and blood pressure regulation in response to an intervention
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targeting hypertension. In conclusion, the identification of SNPs associated with the success of
a hypertension treatment intervention suggests that genetic factors in combination with age may
contribute to an individual’s success in lowering SBP. If these findings prove to be applicable to
other populations, the use of this genetic variation in making patient-specific interventions may help
providers with making decisions to improve patient outcomes. Further investigation is required to
determine the role of this genetic variance with respect to the management of hypertension such that
more precise treatment recommendations may be made in the future as part of personalized medicine.
Keywords: hypertension; GWAS; precision medicine; rural population; SNP-age interaction
1. Introduction
Hypertension (HTN) and its end-organ manifestations including stroke, coronary heart disease,
and chronic renal failure are major contributors to morbidity and mortality in the United States
and globally [1,2]. On average, life expectancy is reduced by five years among those with HTN,
which is responsible for nearly one in every eight deaths worldwide [3]. Multiple important
individual, societal, and environmental variables contribute to an individual’s risk of developing
HTN [4]. Particularly noteworthy is the persistence of racial disparities in HTN prevalence, control,
and untoward outcomes between African Americans (AA) and Caucasians (CAU), despite the fact
that a higher proportion of AAs are both aware of and receive treatment for HTN [5].
Typical intervention strategies used to reduce blood pressure (BP) include implementing strategies
at various levels of patient influence (patient, family, healthcare provider, community level) [6]
and in some cases implementing strategies to enhance control among specific groups, such as
African Americans [7,8]. Such interventions aim to reduce BP by improving medication adherence,
guiding better lifestyle choices, using home BP monitors, addressing clinical inertia in intensifying
anti-hypertensive treatment, using team-based approaches to improve HTN management, and other
strategies [7–11].
Additional factors of interest in the study of HTN include advancing our understanding of how
genes associate with both the presence of HTN and the responsiveness to interventions aiming to
reduce BP, and how genes interact with the many other contributing factors, such as advancing age,
that influence the prevalence of HTN. A better understanding of these genetic influences may inform
the implementation of targeted and personalized therapies that mitigate the untoward consequences
of sustained HTN.
Genome-wide association studies (GWAS) identified associations between specific genetic loci,
mapped by the presence of single nucleotide polymorphisms (SNPs) that represent genetic variation
among populations, and the prevalence of HTN [12–19]. Remarkably, Simino and colleagues [12]
developed a unique approach to analyzing cross-sectional GWAS data by stratifying hypertension-SNP
association data into age brackets, which provided results suggesting that some SNPs associate with BP,
but the magnitude and direction of this association varied by age. However, it is not clear whether these
data, often obtained from large studies of well-defined populations near major medical institutions,
are applicable to subjects in rural areas that often suffer from health disparities. Moreover, it is
not known whether these data are germane given the multifactorial nature and numerous different
environmental modifiers that interact with genes to influence BP [20,21], a phenomenon seen with
other chronic diseases as well [22–24]. The multifactorial nature of chronic diseases distinguishes them
and their study from Mendelian diseases, such as cystic fibrosis, sickle cell anemia, phenylketonuria,
and others, where the presence of specific risk alleles are sufficient to cause a disease phenotype [25–27].
Our team developed and implemented a two-year multi-level intervention, called the Heart
Healthy Lenoir (HHL) project, to improve clinical management of HTN, with a specific focus on
reducing racial disparities in BP levels. The primary outcome of the intervention was the change
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in systolic blood pressure (SBP) from baseline to 12-month follow-up (hereafter denoted by ∆SBP,
calculated as follow-up minus baseline). Five hundred and twenty-five participants with a clinical
diagnosis of uncontrolled hypertension participated in the HHL high BP study. We recruited patients
whose last recorded SBP was ≥150 mmHg in order to enhance the probability of the subjects having
uncontrolled HTN (SBP ≥ 140 mmHg or diastolic blood pressure (DBP) ≥ 90 mmHg) at their
study enrollment visit. Along with baseline survey and biometric data, participants were invited to
provide blood samples for genetic analyses [28]. Our goal was to determine if precision medicine
approaches in a rural population can provide insight into BP regulation and possible responsiveness
to a hypertension intervention.
2. Materials and Methods
2.1. Clinical Approach
2.1.1. Description of High Blood Pressure Study
Details of the design, setting, participants, and implementation of the study are described in
Halladay et al. [29] and Cene et al. [30]. Briefly, we conducted a prospective cohort intervention
study using a community-based participatory approach that included input from a community
advisory committee and the staff at local practices to help inform the intervention content and delivery.
Our cohort consisted of 525 English-speaking patients enrolled from six local practices with
an established clinical diagnosis of uncontrolled hypertension and an office SBP of≥150 mmHg during
a one-year time frame before enrollment. Our multi-component office-based HTN improvement
intervention included strategies at both the practice/organization level (e.g., design team calls, dinner
meetings, practice facilitation, and review of electronic health record data) and at the patient level
(e.g., telephone coaching, home BP monitoring). The telephone coaching part of our intervention was
informed by components of Bosworth’s Take Care of Your Blood Pressure study [31]. We provided
practices with an anti-hypertensive medication algorithm based upon guidance included in the Seventh
Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High
BP (JNC-7) treatment algorithm to which providers, staff, and patients could refer at the point of
care [1].
2.1.2. Description of Lifestyle Study
Two hundred participants in the hypertension intervention were co-enrolled in the HHL
lifestyle study. Detailed information on the study design and methods are published [32].
Briefly, the lifestyle study began with a four-month intervention focused on improving dietary fat
and carbohydrate quality and increasing physical activity. Over the next eight months, participants
received a lifestyle maintenance intervention or could elect to receive a weight loss intervention if their
body mass index (BMI) was ≥25 kg/m2. Patients could thus be in either study or co-enrolled in both.
Hypertension was not a requirement for participation in the lifestyle study.
2.1.3. Study Measures
Baseline and follow-up data were collected as described [29,30,32–34]. Blood pressure
was measured by trained research staff using the Omron HEM-907 automated BP monitor
(Omron Healthcare, Inc., Vernon Hills, IL, USA). A research assistant recorded the average of three
sequential measurements obtained at 60-s intervals and followed JNC-7 guidelines for accurate
measurement technique [1].
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2.2. Genomic and Experimental Analyses
2.2.1. DNA Isolation, Purification, and Quality Control
DNA was purified from a total of 512 HHL participants (see Figure S1 for study participation
information) with an automated system (Autopure LS, Autogen, Holliston, MA, USA). The DNA
samples were quantified in multi-spectral optical density spectrophotometers (SpectraMax Plus,
Molecular Devices, San Jose, CA, USA) at two dilutions in duplicate. Fifteen percent of all DNA
samples were run on agarose gels for quality assurance verification. Final dilutions of DNA (75 ng/µL)
used for genotyping were confirmed using PicoGreen double stranded DNA quantification (Promega,
Madison, WI, USA).
2.2.2. Genotyping on the Illumina Platform
Genotypes were generated from genomic DNA using the Infinium workflow, reagents, equipment,
and software (Illumina, San Diego, CA, USA) essentially as described by the manufacturer. DNA was
amplified, fragmented, precipitated with isopropanol, and resuspended prior to hybridization onto
BeadChips containing 50mer probes. After hybridization, enzymatic single base extension with
fluorescently labeled nucleotides was conducted to distinguish alleles. Hybridized BeadChips were
imaged using an Illumina iScan to determine intensities for each probe. Corresponding genotypes
were extracted from intensity data and called using a standard cluster file within Illumina Genome
Studio software. A Minimal Information About a Microarray Experiment (MIAME) compliant dataset
of the microarray data generated is available at the NCBI database of Genotypes and Phenotypes
(dbGaP, study ID phs001471).
After Genome Studio calls were made, the quality of the genotype calls was reviewed in
detail, examining SNPs with low call rates, SNPs that violated Hardy-Weinberg equilibrium
assumptions, and SNPs that putatively had no variation. After review and correction using segmented
population-based custom clustering, low call rate SNPs were reduced by 10%, and >2000 SNPs with
no apparent variation were adjusted, sometimes manually, to reflect actual population diversity
(Figure S2). The remaining ~175k SNPs with no variation were removed from the study and other
SNPs failing the initial Hardy-Weinberg equilibrium (HWE) testing were re-clustered to a state that met
HWE assumptions, amounting to approximately 3000 and 1000 SNPs in the AA and CAU ancestral
cohorts, respectively (Table S1).
2.2.3. SNP-Level Analysis of Admixture and Relatedness
We excluded SNPs that were less than 80% present across all samples or had fewer than 1.6%
heterozygous calls. Starting with all 512 samples and including data from four HapMap samples
of known population origin, we applied principal components analysis to determine the genetic
population groups and to flag samples with admixture. We also used this analysis to identify pairs of
samples with 68% or more SNP similarity (near relatives) as both admixture and related individuals
can obfuscate GWAS results. In the case of related individuals, we included only the subject with the
largest absolute ∆SBP for data analysis.
2.2.4. Imputing Single Nucleotide Polymorphisms
All HHL DNA samples identified as either AA (305) or CAU (199) were imputed for a total
of 504 imputed samples. The array data were exported into plink format and converted into
chromosome-specific variant call format, applying the following filters: merge replicate probes,
switch the alternate (ALT) or reference (REF) sequence if deemed necessary by reference, exclude
markers where neither REF nor ALT matches the reference, exclude markers where REF is not AGCT.
Additionally, in preparation for Beagle the following filters were further applied: remove markers not
in the reference, fill ALT values in from reference where genotype is entirely homozygous for reference.
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Samples were imputed twice, once with the Michigan imputation server (using Minimac
v2013.7.17 [35] and once with Beagle v4.1 [36]. All 504 samples imputed with Beagle were run
against the 2504-sample reference panel from 1000 genomes. The Haplotype Reference Consortium
(HRC, 65k haplotypes) reference panel was used to run the CAU samples on the Michigan imputation
server, and the Consortium on Asthma among African-ancestry Populations in the Americas (CAAPA)
reference panel was used to run the AA samples on the imputation server. A brief summary of
coverage regarding the panels and how they performed with the target marker set (the markers from
the genotyping array) is provided (Table S2). However, the Illumina genotyping arrays are sparse
compared to the reference panels. We filtered our array data for conformity and the markers remaining
used for the variant calls are indicated (Table S3).
2.2.5. Pre-Modeling Activities
We performed statistical analyses to measure the association of demographic and clinical variables
to the ∆SBP, stratified by ancestry, using a bivariate linear fit or one-way analysis for continuous
variables or categorical variables, respectively (JMP Pro, v12.1, SAS, Cary, NC, USA). We then generated
a multivariable linear model to test the effect of variables in the presence of other clinically relevant
variables and their potential association with ∆SBP (JMP Pro, v12.1) where β0 is the y-intercept and βn
represents the standardized beta coefficient of the effect of each variable:
(1)
2.2.6. Pre-Modeling Activities
We filtered SNPs to include only those with minor allele frequencies >5% and with 100% call-rates.
Next, each SNP was tested for association with baseline SBP or ∆SBP using multivariable linear
regression within each ancestral cohort. The first model accounted for age, gender, and smoking
including interaction terms with age. HetSNP and HomSNP correspond to the heterozygous and
homozygous status of the SNP:
(2)
A second model used for ∆SBP included a variable to account for co-participation in the lifestyle
intervention:
(3)
2.2.7. Baseline Systolic Blood Pressure Association Testing
Risk SNP genotypes were obtained from the microarray data where available. Where not available,
risk SNP genotypes were imputed genotypes from the CAAPA and HRC panels available on the
Michigan Imputation server, according to the ancestry determined for the sample. Where genotypes
were not available on the Michigan Server panel, the genotype was obtained from the Beagle imputation
against the 1000 genomes panel. Specifically, three risk SNPs were imputed with Beagle: rs12408339,
rs17428471, rs4373814. We used Equation (3) to determine p values for SNP associations with
baseline SBP.
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2.3. Human Studies
This study was approved by the Institutional Review Board at the University of North Carolina
at Chapel Hill with data collected from September 2011 to November 2014 and registered as
# NCT01433484 at clinicaltrials.gov. All study participants gave verbal consent for administration




3.1.1. Genetic Ancestry of the Study Population
We evaluated 512 genetic samples obtained from the HHL cohort by principal components
analysis using over 700,000 SNPs (Figures S1 and S2, Table S1) to identify subjects of either African
or European ancestry (Figure 1) as well as relatedness. We then removed subjects with admixture
to identify a subset of genetically unrelated subjects assigned to the office-based HTN improvement
intervention who had BP measurements at baseline and 12-month follow-up, referred to hereafter as the
“HTN cohort,” as well as a smaller cohort of HHL subjects that did not receive the HTN intervention
(Table S4). The HTN cohort was stratified by genetic ancestry into two groups comprised of 193
subjects of AA ancestry and 123 subjects of Northern and Western European (Caucasian American,
CAU) ancestry, respectively (Figure S1).
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ancestral origins are identified (□): CEU, Utah residents with Northern and Western European 
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Nigeria. PC1: principal component 1; PC2: principal component 2. 
3.1.2. Clinical Characteristics of the Study Population 
The AA subjects included in this study were younger, had a greater mean body mass index 
(BMI), and higher mean diastolic BP without differences in mean systolic BP compared to the CAU 
subjects (Table 1). The AA group also had higher rates of diabetes, higher high-density lipoprotein 
cholesterol (HDL-C) values, and were more likely to be prescribed anti-hypertensives from different 






Figure 1. Principal component analysis of all genotyped Heart Healthy Lenoir (HHL) study participants.
Five hundred and twelve HHL samples identified with either Caucasian American (CAU) or African
American (AA) ancestry (#) or admixed samples ( ). HapMap samples of known ancestral origins
are identified (): CEU, Utah residents with Northern and Western European ancestry; CHB, Han
Chinese in Beijing, China; JPT, Japanese in Tokyo, Japan; YRI, Yoruba in Ibadan, Nigeria. PC1: principal
component 1; PC2: principal component 2.
3.1.2. Clinical Characteristics of the Study Population
The AA subjects included in this study were younger, had a greater mean body mass index (BMI),
and higher mean diastolic BP without differences in mean systolic BP compared to the CAU subjects
(Table 1). The AA group also had higher rates of diabetes, higher high-density lipoprotein cholesterol
(HDL-C) values, and were more likely to be prescribed anti-hypertensives from different classes of
anti-hypertensive medications compared to the CAU group.
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Number of genotyped participants 193 123
* Age at enrollment, mean (range) 57 (24–92) 60 (25–91) 0.0103
Male sex, n (%) 60 (31) 41 (33) 0.7113
*** Education: HS or less, n (%) 152 (79) 74 (60) 0.0005
*** Low literacy†, n (%) 52 (29) 12 (10) 0.0002
Employed full or part time, n (%) 71 (37) 47 (38) 0.8124
*** Household income ≤ $40,000 n (%), (missing = 14%) 148 (90) 70 (65) 0.0001
* Currently have health insurance, n (%) 135 (70) 99 (80) 0.0480
Self-rated health good-excellent, n (%) 118 (61) 75 (61) 1.0000
Co-enrollment in lifestyle study, n (%) 84 (44) 43 (35) 0.1579
Cardiovascular Disease Risk Factors
Current cigarette smoker, n (%) 44 (23) 27 (22) 0.8909
* Diabetes (self-report or HbA1c ≥ 6.5), n (%) 94 (49) 42 (34) 0.0143
Total cholesterol (mg/dL), mean (SE) 186 (3.0) 194 (3.4) 0.1715
*** HDL-C (mg/dL), mean (SE) 53 (1.0) 47 (1.3) 0.0003
Systolic BP (mmHg), mean (SE) 138 (1.5) 138 (1.9) 0.8523
* Diastolic BP (mmHg), mean (SE) 83 (1.0) 80 (1.1) 0.0310
Systolic BP ≥140 mmHg, n (%) 84 (44) 54 (44) 1.0000
Physiologic Factors
* Weight (kg), mean (SE) 101 (1.7) 95 (2.4) 0.0307
* Body Mass Index, mean (SE) 37 (0.7) 35 (0.9) 0.0214
Number of comorbidities, mean (SE) 3.4 (0.1) 3.7 (0.2) 0.2956
** Glomerular Filtration Rate (mg/dL), mean (SE) 88 (1.7) 81 (1.7) 0.0045
Medication and Adherence
*** Taking BP lowering medication, n (%) 182 (94) 100 (81) 0.0006
*** Number of BP medication classes, mean (SE) 2.1 (0.1) 1.6 (0.1) 0.0010
Data presented as mean (standard error) or count (proportion): *, **, *** correspond to p < 0.05, 0.01, 0.001,
respectively, via t-test for continuous data or Fisher’s exact test for categorical data between ancestral cohorts.
† Low literacy determined by scoring under 23 using the Short Test of Functional Literacy in Adults. BP: blood
pressure; HDL-C: high-density lipoprotein cholesterol; SE: standard error.
3.2. Identifying Clinically Relevant Variables that Associate with Systolic Blood Pressure
Bivariate and Multivariable Analyses of Clinical Variable Associations with ∆SBP over One Year
Overall, the intervention was successful in lowering SBP in both AA and CAU groups, with
mean ∆SBPs (± standard deviations) of −4.6 ± 23.7 and −9.2 ± 20.5 mmHg in the AA and CAU
participants, respectively (Figure 2). We performed a bivariate analysis of variables of interest with
∆SBP (Table 2). The sign of the estimated beta in this analysis reflects either an increase (+) or decrease
(−) in SBP over one year relative to the variable of interest. We identified a negative association
between ∆SBP and age in both groups, meaning that older participants had a greater decrease in SBP.
We also observed opposite associations between ∆SBP and smoking status in our groups, with smoking
associated with either an increase or decrease in SBP after one year of the intervention in AA or CAU
groups, respectively. Additionally, we identified associations with lifestyle (LS) co-participation and
weight loss in the AA group, suggesting that LS co-participation may have contributed to the ∆SBP in
this group. Although there were differences in both the percentage of subjects taking anti-hypertensives
as well as in the number of classes anti-hypertensives prescribed comparing the AA and CAU groups
(Table 1), within the two groups we did not find any association between ∆SBP and either the number
of different classes of anti-hypertensives or the total number of anti-hypertensives that study subjects
were initially prescribed (Figure S3a–d). Moreover, when we considered all subjects (AA or CAU)
that were prescribed only a single class of medication, there was no difference in ∆SBP (Figure S3e).
Overall, these data suggest that age, smoking, and LS co-participation are trait variables of interest
with respect to ∆SBP.
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Figure 2. Systolic blood pressures of participants enrolled in hypertension intervention. The systolic
blood pressures (SBP, left y-axis) of African American (AA, A, n = 193) or Caucasian (CAU, C, n = 123)
participants in the hypertension intervention at the start of the intervention (0) and after 12 months
of the intervention as well as the change in SBP (∆, right y-axis) after 12 months are represented by
a dot plot and summarized by mean ±95% confidence intervals: **** p < 0.0001 and ** p < 0.01 via the
paired t-test of SBP. The p value of the unpaired t-test comparing the ∆ of AA versus CAU cohorts is
also indicated.
Although bivariate analysis provides some insight into factors that may influence SBP, this
approach does not control for the confounding effects of multiple variables on BP regulation. Therefore,
we performed a multivariable analysis. In Table 3, we show results for our multivariable linear model
for ∆SBP, Equation (1). Interestingly, in this model only the effect of age in both AA and CAU
groups and LS co-participation in the AA group had associations with ∆SBP at p < 0.05. The effect
of weight loss did not impact ∆SBP in this model, likely due to the association of weight loss with
LS co-participation (p = 0.028); therefore, we opted to use the LS variable in lieu of weight loss in
subsequent models.
Table 2. Bivariate analysis of ∆SBP and trait variables. The indicated traits were analyzed for association
with ∆SBP within each ancestral cohort.
AA CAU
Trait Estimate (SE) Estimate (SE)
Age (years) −0.43 (0.14) ** −0. 7 ( .18) *
Lifestyle participation (no) 6.51 (3.42) ‡ 1.77 (3.90)
BMI (per unit) −0.17 (0.19) 0.34 (0.18) ‡
Smoking (some vs. none) 13.68 (8.60) −24.67 (11.87) *
Smoking (some vs. daily) 15.30 (9.26) ‡ −24.67 (12.40) *
Smoking (none vs. daily) 1.61 (4.40) 0.00 (4.62)
Diabetes (no) −2.95 (3.42) −5.77 (3.87)
Gender (male) 2.31 (3.70) 3.15 (3.92)
Weight loss (per percent) −0.66 (0.33) * −0.06 (0.29)
Results are reported as the estimate (β or mean difference for continuous or nominal variables, respectively)
and standard error (SE); ‡, *, ** indicate p ≤ 0.10, 0.05, 0.01, respectively.
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Table 3. Multivariable regression analysis of ∆SBP and traits of interest. The indicated traits were
analyzed for association with ∆SBP in a multivariable linear model within each ancestral cohort.
AA CAU
Trait Estimate (SE) Estimate (SE)
Age (years) −0.59 (0.15) *** −0.38 (0.19) *
Lifestyle participation (no) 3.49 (1.73) * 0.91 (1.84)
BMI (per unit) −0.34 (0.21) 0.19 (0.25)
Smoking history (ever) −2.09 (2.14) −3.89 (2.41)
Diabetes (no) −2.52 (1.72) −1.84 (2.11)
Gender (male) 0.03 (1.90) 2.11 (1.91)
Weight loss (per percent) −0.39 (0.33) −0.16 (0.29)
Results are reported as the estimate (β or mean difference for continuous or nominal variables, respectively)
and standard error (SE); *, *** indicate p ≤ 0.05, 0.001, respectively.
3.3. Association Analysis of Candidate Blood Pressure Polymorphisms in a Rural Population
Our multivariable analysis informed the generation of two equations to test the association of the
SNP main effect (either heterozygous or homozygous status) in the context of other variables identified
in Table 3 (age), as well as historically relevant variables associated with BP control such as gender [37]
and smoking status [20]. Given the strong effect of age, we also included interactions terms for age
and each variable. Equation (2) was used to test the association of SNPs with SBP or ∆SBP levels.
Equation (3) included an additional term to control for co-participation in the LS intervention and was
used to test the association of SNPs with ∆SBP.
For precision medicine to impact population health, we must consider if and how data, such as
genetic variation, can be used as potential risk indicators for both populations and individual patients.
Several large GWAS identified risk SNP variants associate with BP [18,19,38,39]. Traditionally, GWAS
are performed on large and affluent patient populations, primarily of European ancestry. One of
our prime objectives was to determine whether BP risk SNPs from the aforementioned studies apply
to our study population. Therefore, we tested the association of baseline SBP with the 19 and 29
previously identified risk SNPs from AA and CAU subjects, respectively. Remarkably, we replicated 13
of these associations within our HTN cohort, including the main SNP effect as well as with the SNP-age
interaction variable (Table 4, Table S5). In fact, four loci originally identified in European cohorts also
associated with baseline SBP in our AA subjects. Given that these variants associate with HTN and
other cardiovascular comorbidities, we hypothesized that these same SNPs would also associate with
the change in SBP after one year of our intervention, as the same genetic influences of BP regulation may
also contribute to how individuals respond to BP lowering interventions. Next, we tested the risk SNPs
for their association with ∆SBP, performing a similar association analysis. Only one (rs592582) of the
13 SNPs that associated with baseline SBP also associated with ∆SBP (Table 4, Table S6). These results
suggest that variation associated with hypertension may be distinct from variation associated with
responsiveness to HTN interventions.
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Table 4. Associations of previously identified risk single nucleotide polymorphisms (SNPs) with either
baseline SBP or ∆SBP.
dbSNP





rs592582 XR_001739753 2 157773386 AA ↑ [↓] ↓ [↑]
rs243601 C21orf91-OT1 21 19159766 AA ↑ ↓
rs243603 C21orf91-OT1 21 19160300 AA ↑ ↓
rs243605 C21orf91-OT1,C21orf91 21 19161120 AA ↑ ↓
rs243607 C21orf91-OT1,C21orf91 21 19161515 AA ↑ ↓
rs2220511 C21orf91-OT1,C21orf91 21 19164911 AA ↑ ↓
rs2258119 C21orf91 21 19167479 AA ↓ ↑
rs1799945 HFE 6 26091179 AA † ↓ ↑
rs381815 PLEKHA7 11 16902268 AA † ↓ ↑ ↑ ↓
rs3184504 SH2B3 12 111884608 AA † ↑ ↓
rs2521501 FES 15 91437388 AA † ↓ ↑
rs17477177 CTB-30L5.1 7 106411858 CAU ↑ ↓
rs1378942 CSK 15 75077367 CAU ↓ ↑
The Single Nucleotide Polymorphism Database identifier (dbSNP ID) from the National Center for Biotechnology
Information, associated gene, chromosome (chr), position in GRCh37, and the HTN ancestral group of SNP main
effects and SNP-age interactions that associated with baseline SBP are indicated by arrows. Associations of either the
heterozygous (HET) or homozygous (HOM) genotype with ∆SBP are indicated by arrows in brackets []. The arrows
indicate either positive (↑) or negative (↓) estimates (β) of the SNP main effect or the SNP-age interaction term on
SBP (or ∆SBP) at p < 0.05. SNPs identified initially in CAU populations that associated with SBP in our AA cohort
are indicated (†).
3.4. Genome-Wide Association Analysis of Genetic Variation with ∆SBP
3.4.1. Single Nucleotide Polymorphism Associations with ∆SBP
We extended our ∆SBP association analyses to other regions in the genome using our HHL cohort
to identify other SNPs that associate with the responsiveness of our intervention. Approximately
585,000 probes were mapped to unique SNPs and matched to p values produced by our linear model
that adjusted for age, gender, and smoking using Equation 2. The quantile-quantile probability (Q-Q)
plots revealed that no single SNP reached genome-wide significance at p < 1 × 10−8, which was not
surprising given the complex phenotype of BP regulation and the size of our study. However, the Q-Q
plots were skewed in p values for the homozygous term and the homozygous:age interaction term
starting at observed p values less than 1 × 10−4, and hence we restricted our analyses to SNPs in these
regions (Figure S4). Knowing the confounding effect of LS co-participation in our model of ∆SBP
(Table 3), we first tested the impact of the LS correction term in our multivariable model. To account
for the LS effect, we included an additional 58 and 22 subjects to the AA and CAU groups that were
only exposed to the LS intervention (and not the HTN intervention, Table S4). We compared the
p values of the SNP main effect and SNP-age interaction with and without the LS variable in the model,
Equations 2 and 3. This allowed us to identify SNPs confounded by LS co-participation (Figure 3,
Figure S5). Additionally, consistent with our multivariable analysis, the inclusion of the LS variable
had a larger effect in the AA group compared with the CAU group. The increased effect size in the
AA group was likely due to the higher baseline SBP in the co-enrolled AA patients compared to
the CAU patients (142.6 and 139.5 mmHg, respectively). This approach allowed us to identify 26
and 74 candidate SNPs (p range 1 × 10−4 – 1.2 × 10−6) that associated with ∆SBP and were unaffected
by LS co-participation in the AA and CAU groups, respectively (Figure 4, Tables S7 and S8).
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Given the discovery nature of our study and the cohort design of the HTN intervention, we 
applied a workflow to filter, refine, and validate candidate SNPs (Figure 5). First, we identified 
genomic regions represented by multiple SNP associations to ΔSBP, resulting in four and 15 loci in 
the AA and CAU groups, respectively (Tables 5 and 6). Consistent with the SNP-age associations 
seen with baseline SBP, three of the four loci from the AA group and 13 of the 15 loci from the CAU 
group also had SNP-age interactions with ΔSBP (Figure 5). Given the recent observation of gene–age 
interactions on BP [12] and our results reported here, we further explored the gene-age observation 
by stratifying each ancestral group by median age. Using this approach, we identified SNPs that 
associated with either a successful or unsuccessful intervention (mean ΔSBP < 0, or ≥ 0, respectively) 
depending on age (Figure 6), suggesting these gene-age interactions may have influenced a 
participant’s response to the HTN intervention. 
Figure 3. Lifestyle co-participation correction on SNP discovery. The effect of including a lifestyle
co-participation variable (LS) in the model for ∆SBP is represented by a scatter plot of the p values of
the Age:HO interaction ter with or without the LS variable on either the y- or x-axis, respectively,
in the (a) or C (b) cohort. Regression analysis (dashed line) indicates the overall effect of the
correction by how far it deviates from no change (solid line). Individual SNPs that passed the discovery
cutoff of p < 1 × 10−4 with the LS correction or SNPs that were confounded by LS participation and
excluded from a ditional analyses are indicated by either magenta- or green-filled points, respectively.
Open points represent additional SNPs with no association to ∆SBP (p > 1× 10−4). HOM: homozygous
status of the SNP.
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Figure 4. The SNP main effect associated with a change in blood pressure after 12 months of
the intervention. The change in SBP (∆SBP) after 12 months of the intervention in either (a) AA
or (b) CAU study participants (n = 193 and 123, respectively), represented by a dot plot and summarized
by the median. The p value of the association of the HomSNP variable (HOM) with ∆SBP for each SNP
is indicated. The dashed line represents the mean ∆SBP for each cohort.
3.4.2. Refining SNPs of Interest and Identifying SNP-Age Interactions
Given the discovery nature of our study and the cohort design of the HTN intervention, we applied
a workflow to filter, refine, and validate candidate SNPs (Figure 5). First, we identified genomic regions
represented by multiple SNP associations to ∆SBP, resulting in four and 15 loci in the AA and CAU
groups, respectively (Tables 5 and 6). Consistent with the SNP-age associations seen with baseline
SBP, three of the four loci from the AA group and 13 of the 15 loci from the CAU group also had
SNP-age interactions with ∆SBP (Figure 5). Given the recent observation of gene–age interactions on
BP [12] and our results reported here, we further explored the gene-age observation by stratifying
each ancestral group by median age. Using this approach, we identified SNPs that associated with
either a successful or unsuccessful intervention (mean ∆SBP < 0, or ≥ 0, respectively) depending on
age (Figure 6), suggesting these gene-age interactions may have influenced a participant’s response to
the HTN intervention.
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rs7906433 intergenic KLF6 10 3888845 ↓ ↑ ↑ ↓ 
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The arrows indicate either positive (↑) or negative (↓) estimates (β) of the SNP or SNP-age interaction 
on ΔSBP at p < 1 × 10−4. 
Figure 5. Workflow to identify genetic regions of interest that associate with ∆SBP. We used
a series of data filters (SNP filters) to refine potential loci associated with the responsiveness to
our HTN intervention. The number of individual SNPs associated with ∆SBP within each ancestral
group is indicated (SNP main effect) and the remaining number of SNPs after each filter (↓) as
well as the corr sponding number of loci represented by the SNPs r provided in parentheses:
#SNPs (#loci). eQTL: xpression quantitative trait loci; CVD RF: cardiovascular disease risk factor;
AQP4-AS1: Aquaporin 4 antisense RNA 1; PADI2: protein-arginine deiminase type II.
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Figure 6. SNP–age interactions associated with a change in blood pressure after 12 months of the
intervention. The change in SBP (∆SBP) after 12 months of the intervention in either (a) AA or
(b) CAU study participants (n = 193 and 123, respectively), represented by dot plot and summarized by
the median. To demonstrate the SNP-age interaction, ach cohor was stratified over the median age.
The p value of the association of the interaction betwe n ag and the HomSNP variable (Age:HOM)
with ∆SBP for each SNP is indicated. The dashed line represents the mean ∆SBP for each cohort.
Table 5. Loci with multiple SNPs that associate with ∆SBP in the AA cohort. The dbSNP identifier (ID),
description of region, associated gene, chromosome (chr), and position in GRCh37 of the SNP main
effects and SNP-age interactions that associated with ∆SBP are indicated by arrows.
dbSNP ID Region Gene(s) Chr GRCh37 β HET β HOM β Age:HET
β Age:
HOM
rs16942954 intronic AQP4-AS1, CHST9 18 24501350 ↑ ↓
rs16942955 intronic AQP4-AS1, CHST9 18 24502493 ↑ ↓
rs232358 intronic, 3’ UTR AQP4-AS1, HST9 18 24492099 ↓
rs380625 intronic, 3’ UTR AQP4-AS1, HST9 18 24493117 ↓
rs1181704 intronic, 3’ UTR AQP4-AS1, CHST9 18 24492641 ↓
rs11597228 interge ic CELF2 10 10660838 ↓ ↑
rs4747873 intergenic CELF2 10 10686085 ↓ ↑
rs7906433 intergenic KLF6 10 3888845 ↓ ↑ ↑ ↓
rs12255472 intergenic KLF6 10 4466023 ↑ ↓
The arrows indicate either positive (↑) or negative (↓) estimates (β) of the SNP or SNP-age interaction on ∆SBP
at p < 1 × 10−4.
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Table 6. Loci with multiple SNPs that associate with ∆SBP in the CAU cohort. The dbSNP identifier
(ID), description of region, associated gene, chromosome (chr), and position in GRCh37 of the SNP
main effects and SNP-age interactions that associated with ∆SBP are indicated by arrows.
dbSNP ID Region Gene(s) Chr GRCh37 β HET β HOM β Age:HET
β Age:
HOM
rs2014725 intronic PADI2 1 17417253 ↓ ↑
rs2235910 intronic PADI2 1 17425829 ↓ ↑
rs737428 intronic PADI2 1 17429185 ↓ ↑
rs4949959 intergenic RWDD3 1 95766707 ↓ ↑ ↑ ↑
rs4950044 intergenic RWDD3 1 95766797 ↓ ↑ ↑ ↓
rs6683355 intergenic RWDD3 1 95773106 ↓ ↑ ↑ ↓
rs7519220 intergenic SRP9, ENAH 1 225863345 ↓ ↑
rs7365361 intergenic SRP9, ENAH 1 225864622 ↓ ↑
rs943759 intergenic LOC102723834 1 225886318 ↓ ↑
rs6576973 3’ UTR ARID5A 2 97218367 ↓ ↑
rs7608325 intergenic KANSL3 2 97305080 ↑
rs7690085 intronic FSTL5 4 162709000 ↑ ↓ ↓
rs13130537 intronic FSTL5 4 162718372 ↓ ↓ ↑ ↑
rs10026821 intronic SORBS2 4 186540503 ↑ ↓
rs10030246 intronic SORBS2 4 186541887 ↑ ↓
rs37957 intronic LOC100505921,LOC105375139 7 8000971 ↓
rs37968 intronic LOC100505921,LOC105375139 7 8005973 ↓
rs1468594 intronic GLCCI1 7 8122313 ↓ ↑ ↑ ↓
rs10966220 intergenic IZUMO3, ELAVL2 9 24113158 ↓
rs10812027 intergenic IZUMO3, ELAVL2 9 24113936 ↓
rs10886170 intergenic GHITM, NRG3 10 85091864 ↓ ↑
rs10886214 intergenic GHITM, NRG3 10 85127739 ↓ ↑ ↑ ↓
rs11244854 intronic ADAM12 10 127850629 ↓
rs1674927 intronic ADAM12 10 127852395 ↓
rs7337547 intergenic SPRYD7, KPNA3 13 50443527 ↓
rs11617754 intronic SPRYD7 13 50501980 ↑
rs9805613 intergenic SLITRK6 13 86982353 ↑ ↓
rs9302073 intergenic SLITRK6 13 87002553 ↑ ↑
rs8021103 intronic LOC105370510 14 56177363 ↑ ↓ ↓ ↑
rs10498477 intronic LOC105370510 14 56180099 ↑ ↑ ↓ ↓
rs2134919 intergenic EXOC5, OTX2 14 57412758 ↑ ↓ ↓ ↑
rs6573129 intergenic EXOC5, OTX2 14 57648321 ↓ ↑
rs7158266 intergenic EXOC5, OTX2 14 57648751 ↓ ↑
rs10136042 intergenic EXOC5, OTX2 14 57665761 ↑ ↑ ↓
rs10135064 intergenic EXOC5 14 57668859 ↓ ↑
rs3742578 missense,3’ UTR EXOC5 14 57672715 ↓ ↓ ↓ ↑
rs7141911 3’ UTR EXOC5 14 57672871 ↓ ↑
rs198480 intergenic CTNNBL1, BLCAP 20 36280827 ↑ ↓
rs1928630 intergenic CTNNBL1, BLCAP 20 36286035 ↑ ↑ ↓
The arrows indicate either positive (↑) or negative (↓) estimates (β) of the SNP or SNP-age interaction on ∆SBP
at p < 1 × 10−4.
3.4.3. Single Nucleotide Polymorphisms Associate with Changes in Gene Expression and Other
Cardiovascular Risk Factors
Whereas SNP associations can inform us of possible heritable linkages to disease, integrating
data from association studies with expression quantitative trait locus (eQTL) studies was shown by
us [40,41] and others [42] to help identify genes that may play functional roles in a complex trait
such as BP regulation. Therefore, we identified the multi-hit loci that also associated with a change
in tissue-specific gene expression using well-defined, independent samples (range 93–338 samples,
false discovery rate < 1%) [43]. We identified a single locus in each cohort comprised of three eSNPs
(expression SNP) in perfect linkage disequilibrium in the AA cohort (AQP4-AS1, p = 1× 10−6) as well as
three eSNPs in high linkage disequilibrium (R2 > 0.97) in the CAU cohort (PADI2, p range = 1.1 × 10−4
to 2.8 × 10−101). AQP4-AS1 is an uncharacterized gene encoding a long non-coding RNA of unknown
function. The expression of AQP4-AS1 is restricted to specific regions of the brain. Interestingly,
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the only tissue with a corresponding eQTL for AQP4-AS1 is in the nucleus accumbens region of
the brain. Neurons in the nucleus accumbens are involved in inhibiting fight-or-flight responsive BP
increases [44]. Moreover, in a rodent chronic hypertension model, animals with high BP had a reduction
in both dendritic spine density and length in neurons within the nucleus accumbens, a pathology that
worsened with age [45]. On the other hand, PADI2 is more ubiquitously expressed throughout the
body with the highest levels in whole blood, skeletal muscle, and the spinal cord. We observed robust
eQTLs across multiple tissues (Table S9), with the strongest eQTL found in whole blood (Figure 7).
PADI2 encodes an enzyme involved in protein citrullination, a clinically targeted pathway implicated
in a range of diseases such as atherosclerosis, rheumatoid arthritis, lupus, and multiple sclerosis [46].
Finally, given the limited size of our study, the numerous risk factors that contribute to BP
regulation, and the sparsity of association between previously identified BP SNPs and ∆SBP (Table 4),
we leveraged the power of larger GWAS studies to determine if our candidate loci associate with
other cardiovascular disease risk factors. We validated our candidate SNPs in larger cohorts [47]
to broadly look at cardiovascular risk factor associations with our candidate SNPs. Interestingly,
the three AQP4-AS1 SNPs associated with BMI (p range 0.011–0.013) [48] whereas rs737428 and
rs2014725 in PADI2 associated with either low-density lipoprotein cholesterol (p = 0.017) [49] or total
cholesterol (p = 0.047) [50]. These data suggest that these loci may be involved in processes important
to cardiovascular health and responsiveness to HTN interventions.
4. Discussion
We explored associations of SNPs and BP change in a cohort of African American and Caucasian
participants (Figure 1) during a one-year multi-level intervention aimed to reduce BP in patients with
established HTN in Eastern, NC (USA) (Figure 2). Remarkably, within our small, rural population of
study participants in a region of the country that suffers disproportionally from higher cardiovascular
disease risk, we associated several known genetic variants with baseline SBP levels (Table 4) by
controlling for age, gender, and smoking. Moreover, the SNP rs592582 also associated with the
responsiveness to the intervention. The minor allele of rs592582 associated with higher baseline
SBP and lower SBP after one year, suggesting that this SNP not only associates with the presence
of hypertension, but also associates with responsiveness to interventions like those employed in the
HHL study. The remaining candidate SNPs that associated with baseline SBP did not associate with
the responsiveness to the intervention, which prompted us to perform an unbiased genome-wide
association analysis of SNPs with ∆SBP in combination with exclusionary data filtering (Figure 5) to
identify other genetic factors that may contribute to the intervention response. We identified four and
15 loci in either our AA or CAU groups that were identified by multiple SNPs with either SNP main
effects and/or SNP–age interactions that associated with a change in SBP (Figure 4, Tables 5 and 6).
Additionally, we explored the interaction of participant age and SNPs to evaluate the potential impact
of age on the responsiveness to the intervention within a SNP group. Several of these loci identified
genotypes in which the BP increases or decreases after one year of the intervention depended on the
age group of the participants (Figure 6, Tables 5 and 6). Our observation of gene–age interactions with
BP is consistent with other recent studies that also observed an influence of age on the association of
SNPs with cardiovascular risk factors such as SBP or BMI [12,51]. Hence, the impact of age on SNP
associations with the responsiveness to our HTN intervention may provide further insight into the
underlying biology of a why certain individuals respond differently to hypertension treatments and
the possible influence of age on the effectiveness of the intervention.
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Figure 7. Expression of quantitative trait loci involving candidate SNPs associated with ΔSBP. Cis 
eQTL analysis of the eSNP rs232358 and rs2014725 with the number of subjects, genotype, and 
corresponding expression levels of either (a) AQP4-AS1 or (b) PADI2 is represented by boxplots (5–
95% confidence intervals) with outliers identified (open circles). The p value and beta coefficient (β) 
of the linear regression are noted. 
Our approach led us to two genes of interest, AQP4-AS1 and PADI2. These two genes and the 
specific variants we identified also associated with other important cardiovascular disease risk 
factors such as BMI and blood lipids in other independent cohorts [48,49], suggesting that these loci 
play a role in cardiovascular health risk. Additionally, these SNPs associated strongly with the 
expression of the gene where they are located (Figure 7), identifying these as eSNPs and perhaps 
indicating a functional role for these variants in our interventional response. AQP-AS1 is a long 
non-coding RNA comprised of 10 overlapping non-coding RNA (ncRNA) transcripts of unknown 
function conserved in both mice and zebrafish [52,53]. PADI2, however, is known to encode a 
peptidyl arginine deiminase that catalyzes the post-translational deimination of proteins by 
converting arginine residues into citrullines, including myelin basic protein, vimentin, actin, and 
histones [54]. The eSNPs we identified associated with a robust change in PADI2 expression in 
multiple tissues including blood cells, heart, aorta, and both visceral and subcutaneous adipose 
(Table S9). Altered PADI2 activity is implicated in neurodegenerative and inflammatory diseases 
[54] and most recently, vascular angiogenesis [55]. PADI2 expression and anti-citrullinated protein 
antibodies were higher in smokers, suggesting that increased PADI2 expression, particularly in 
genetically susceptible subjects (Figure 7b), promotes more robust pathophysiological responses to 
environmental stressors [56–58]. Our data suggest that these PADI2 eSNPs and the expression of 
PADI2 may be have differential effects on blood pressure regulation depending on age (Figure 6b) 
and may be useful in understanding an individual’s response to blood pressure interventions, 
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Figure 7. Expression of quantitative trait loci involving candidate SNPs associated with ∆SBP. Cis eQTL
analysis of the eSNP rs232358 and rs2014725 with the number of subjects, genotype, and corresponding
expression levels of either (a) AQP4-AS1 or (b) PADI2 is represented by boxplots (5–95% confidence
intervals) with outliers identified (open circles). The p value and beta coefficient (β) of the linear
regression are noted.
Our approach led us to two genes of interest, AQP4-AS1 and PADI2. These two genes and the
specific variants we identified also associated with other important cardiovascular disease risk factors
such as BMI and blood lipids in other independent cohorts [48,49], suggesting that these loci play
a role in cardiovascular health risk. Additionally, these SNPs associated strongly with the expression
of the gene where they are located (Figure 7), identifying these as eSNPs and perhaps indicating
a functional role for these variants in our interventional response. AQP-AS1 is a long non-coding RNA
comprised of 10 overlapping non-coding RNA (ncRNA) transcripts of unknown function conserved in
both mice and zebrafish [52,53]. PADI2, however, is known to encode a peptidyl arginine deiminase
that catalyzes the post-translational deimination of proteins by converting arginine residues into
citrullines, including myelin basic protein, vimentin, actin, and histones [54]. The eSNPs we identified
associated with a robust change in PADI2 expression in multiple tissues including blood cells, heart,
aorta, and both visceral and subcutaneous adipose (Table S9). Altered PADI2 activity is implicated
in neurodegenerative and inflammatory diseases [54] and most recently, vascular angiogenesis [55].
PADI2 expression and anti-citrullinated protein antibodies were higher in smokers, suggesting that
increased PADI2 expression, particularly in genetically susceptible subjects (Figure 7b), promotes more
robust pathophysiological responses to environmental stressors [56–58]. Our data suggest that these
PADI2 eSNPs and the expression of PADI2 may be have differential effects on blood pressure regulation
depending on age (Figure 6b) and may be useful in understanding an individual’s response to blood
pressure interventions, particularly in smokers.
Other dietary supplement studies and medication studies evaluated SNP associations with BP
change in Han Chinese cohorts. Gu and Kelly tested the effectiveness of sodium and potassium
supplementation, respectively, on a subsample of hypertensive patients that were part of the Genetic
Epidemiology Network of Salt Sensitivity Study [37,59]. Gu et al. [37] examined associations between
11 renin-angiotensin-aldosterone-system candidate genes with SBP, DBP, and mean arterial BP change
among 1860 Han Chinese subjects who either had HTN or were the sibling, offspring, or spouse
of the individuals with HTN. This cohort consumed a low sodium diet for seven days followed by
a high sodium diet for an additional seven days. Five SNPs were independently associated with BP
responses to a low sodium diet, while just one was associated with BP response to a high sodium diet.
They also shared findings of two additional SNPs that were significantly associated with BP reduction
in only males who were exposed to the low sodium diet. The investigators suggested that these
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genes may play a critical role in the salt sensitivity of BP and could help identify patients that may
benefit most from a low sodium diet. Furthermore, using participants from this same GenSalt study,
Kelley et al. [59] performed a separate analysis on 1906 study subjects that were exposed to a high
sodium diet for 14 days, but were additionally provided 60 mmols of potassium daily for the last
seven days. Their results identified regions on chromosomes 3 and 11 that may harbor susceptibility
loci for dietary potassium sensitivity and a novel variant in the angiotensin II receptor suggested to be
a strong predictor of BP response to potassium sensitivity. As in Gu’s work, they suggest that such
findings may provide insights into the pathophysiology of hypertension and the genetic mechanisms
that underlie potassium sensitivity. They too concluded that the ultimate value of these types of
discoveries might be in guiding people with specific genotypes to dietary interventions that may
provide the greatest impact on BP control.
Multiple anti-hypertensive medication trials have been performed to attempt to identify SNPs
associated with responsiveness to individual classes of anti-hypertensives [60,61]. Additional studies
identified SNPs associated with opposite effects on a subject’s BP with different classes of
anti-hypertensive medications [62]. For example, some SNPs are associated with a BP reduction in
response to one class of medication (e.g., angiotensin receptor blockers) and a BP increase in response
to other classes (e.g., diuretics). The results from Turner et al. [62] and our study presented here further
the call to develop personalized medicine approaches in treating patients with hypertension, allowing
personal (genetic- and age-based) recommendations for specific combinations of drugs. As in our
study, few findings in the these aforementioned medication studies reached the traditional level of
statistical significance deemed sufficient in GWAS [63]; however, many of the SNPs identified in these
studies and ours are potentially important to both disease etiology and tailoring treatments for HTN.
Limitations: As a cohort study reporting pre-post measures, we cannot rule out the possibility that
the observed changes in BP may be due to secular trends or other factors that were not captured in our
data collection and were not instigated by the multi-level intervention per se. The pragmatic nature of
implementing this kind of an intervention with research-naïve clinical partners was both a limitation
and a strength [29]. We designed and implemented the intervention with broad stakeholder input
to maximize feasibility and sustainability, but in a multi-level intervention in “real world” practices,
there is no way to disentangle the effect of any particular aspect of the intervention as being more or
less important in BP control. Likewise, we did not have a measure of medication adherence beyond
self-report, an important component that needs to be addressed for a broad range of diseases if we
are to move forward with precision medicine approaches to care. Our research teams and practicing
clinicians are keenly interested in including anti-hypertensive medication metabolite data in both
trials and routine care as a measure of patient compliance and adherence. This approach could
reliably identify which anti-hypertensive medications are being taken by individual patients. We did
not find any associations between different measures of medication exposure and the effectiveness
of the intervention. However, designing studies that focus both on health disparities and specific
anti-hypertensives may identify gene-drug interactions that could ultimately aid in using genetic data
as a component of blood pressure care.
Additionally, we tested for genetic variation associations using a platform ensuring broad
coverage across the genome that captures variation in both of our ancestral groups, but certainly
there could be additional, important genetic variation that contributed to the responsiveness to the
intervention that was not represented on our arrays or imputation panels. Due to the small sample size,
we used an exploratory p value to establish significance in this study. Additionally, for our modeling
work, not all variables retained in our multiple regression model were independently associated with
the outcome within each race. We included variables noted in the literature to be associated with BP
outcomes in other papers, but in some cases from very different populations [20,37,64]. Without the
data of prior studies on populations, such as that we had in the HHL study, we decided to include
the variables listed. Lastly, our study population was from a small region in Eastern NC. Thus, our
results should not be generalized to larger populations. However, the genetic ancestry of our study
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population is reflective of study populations from large US-based GWAS studies; hence, we believe that
our population is reasonably representative of the larger African American and Caucasian population
in the US.
5. Conclusions
Our results support the concept that genetic variation data from large association studies can be
utilized at a local, practice-based level to help identify genetic risk for HTN. Furthermore, by measuring
individual responses to HTN interventions, we can start to identify genetic variants and other
important factors identified in our study, such as age, that could ultimately be used to guide treatments.
Implementing more HTN interventions that include genomic analyses across multiple locales and
communities will allow us to determine the impact and utility of precision medicine on directing
treatments for HTN. We encourage investigators to continue to find solutions for the numerous
influences on patients with HTN that will allow us to reduce the untoward effects on the families and
communities affected by this disease.
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